Arvinas (NASDAQ:ARVN) Trading Down 3.3% - Should You Sell?

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report)'s share price traded down 3.3% during trading on Thursday . The stock traded as low as $18.09 and last traded at $18.11. 35,509 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 734,522 shares. The stock had previously closed at $18.73.

Wall Street Analyst Weigh In

A number of brokerages have commented on ARVN. Oppenheimer decreased their price objective on Arvinas from $50.00 to $40.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. BTIG Research initiated coverage on Arvinas in a report on Tuesday, December 10th. They set a "buy" rating and a $69.00 price target for the company. Guggenheim restated a "buy" rating on shares of Arvinas in a report on Thursday, December 12th. Stephens began coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an "overweight" rating and a $55.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and set a $87.00 price target on shares of Arvinas in a report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $63.50.

Arvinas Stock Up 1.9 %

The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -4.09 and a beta of 1.82. The stock's fifty day moving average is $24.20 and its 200-day moving average is $25.34.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.20. The firm had revenue of $102.40 million during the quarter, compared to the consensus estimate of $60.56 million. During the same quarter in the prior year, the company earned ($1.18) EPS. Arvinas's quarterly revenue was up 196.0% on a year-over-year basis. As a group, equities research analysts predict that Arvinas, Inc. will post -3.22 earnings per share for the current fiscal year.

Institutional Trading of Arvinas

A number of large investors have recently bought and sold shares of the business. Quest Partners LLC acquired a new stake in shares of Arvinas during the second quarter worth $42,000. nVerses Capital LLC bought a new position in Arvinas during the 3rd quarter worth about $39,000. Amalgamated Bank raised its stake in shares of Arvinas by 29.6% in the 2nd quarter. Amalgamated Bank now owns 2,223 shares of the company's stock valued at $59,000 after purchasing an additional 508 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock valued at $61,000 after purchasing an additional 440 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after buying an additional 2,601 shares during the period. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.